Scientific
Discussion
Request

Clinical Studies

< Treatment-Naïve

Clinical Studies

< Treatment-Naïve

GEMENI and GEMEINI 2 Studies

< Clinical Studies

GEMENI and GEMEINI 2 Studies Results

< GEMENI and GEMEINI 2 Studies

Product Information

< Treatment-Naïve

TANGO Studies: Data in Virologically Suppressed, Treatment-Experienced Patients

< Clinical Studies

SWORD-1 and SWORD-2 Studies

< Juluca

Sword Results

< SWORD-1 and SWORD-2 Studies

Data in Patients Switching to a Tivicay-Based Regimen

< Tivicay + 2NTRIs

Product Information Results

< Stable Switch

< Clinical Studies

Tivicay-Based Regimens

< Tivicay-Based Regimens Results

Data in Treatment-Experienced Patients Naïve to Integrase Inhibitors

< Tivicay-Based Regimens Results

Data in Treatment-Experienced Patients Naïve to Integrase Inhibitors

< Treatment Experienced

Product Information Results

Triumeq

< Special Populations

Triumeq Results

< Start

Tivicay-Based Regimens

< Special Populations

Data in Pediatric Patients (MI letter)

< Tivicay-Based Regimens

Data in Pediatric Patients Results

< Data in Pediatric Patients

Tivicay-Based Regimens

< Special Populations

Occurance of Neural Tube Defects

< Tivicay-Based Regimens

Occurance of Neural Tube Defects Results

< Occurance of Neural Tube Defects

Special Populations

< Special Populations

Availability in the US and EU

< Long-Acting Cabotegravir + Ripivirine

How to handle missed doses

< Dosage, Administration, and Delivery

Efficacy and Safety of Monthly Administration in Virologically Suppressed Patients

< Treatment

Monthly Administration

< Efficacy and Safety of Monthly Administration in Virologically Suppressed Patients

Monthly Administration

< Monthly Administration

Monthly Administration

< Efficacy and Safety of Monthly Administration in Virologically Suppressed Patients

Every 2 month administration

< Efficacy and Safety of Monthly Administration in Virologically Suppressed Patients

Every 2 month administration

< Efficacy and Safety of Monthly Administration in Virologically Suppressed Patients

Treatment-Emergent Resistance Data

< Long-Acting Cabotegravir + Ripivirine

Conference Presentation

< Treatment-Emergent Resistance Data

Patient Reported Outcomes

< Long-Acting Cabotegravir + Ripivirine

Monthly administration

< Patient Reported Outcomes

Every 2 month administration

< Patient Reported Outcomes

Occurrence of Injection Site Reactions

< Long-Acting Cabotegravir + Ripivirine

Monthly administration

< Occurrence of Injection Site Reactions

Every 2 month administration

< Occurrence of Injection Site Reactions

PrEP

< Long-Acting Cabotegravir + Ripivirine

Weight Gain

< Topics of Interest

Baseline Resistance

< Topics of Interest

Use in Patients with M184V/I Resistance Mutation

< Dovato

Rates of M184V/I Resistance Mutation at Screening

< Topics of Interest

Use in Patients with Baseline RT or INSTI Resistance

< Juluca

Use in Patients with Baseline RT or INSTI Resistance

< Triumeq

Product information

< Topics of Interest

Tivicay-Based Regimens

< Weight Gain

Rapid-Start

< Start

Clinical Studies

< Rapid-Start

Dovato

< Clinical Studies

Heavily Treatment Experienced

< Start

Safety Data Results

< Fostemsavir Results

Mechanism of Action Results

< Clinical Pharmacology Results

Overview of HTE Patients Results

< Fostemsavir Results

BRIGHTE Overview Results

< BRIGHTE Results

Product Information Results

< Heavily Treatment Experienced

DTG/ABC/3TC

< Dosing and Administration

DTG dispersible

< Dosing and Administration

Fostemsavir

< Dosing and Administration

Cabotegravir and Rilpivirine

< Dosing and Administration